scPharmaceuticals (SCPH) Competitors $5.56 -0.29 (-4.88%) As of 02:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SCPH vs. ZYME, ORIC, NAGE, MENS, SION, REPL, GHRS, XERS, SNDX, and TRVIShould you be buying scPharmaceuticals stock or one of its competitors? The main competitors of scPharmaceuticals include Zymeworks (ZYME), Oric Pharmaceuticals (ORIC), Niagen Bioscience (NAGE), Jyong Biotech (MENS), Sionna Therapeutics (SION), Replimune Group (REPL), GH Research (GHRS), Xeris Biopharma (XERS), Syndax Pharmaceuticals (SNDX), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry. scPharmaceuticals vs. Its Competitors Zymeworks Oric Pharmaceuticals Niagen Bioscience Jyong Biotech Sionna Therapeutics Replimune Group GH Research Xeris Biopharma Syndax Pharmaceuticals Trevi Therapeutics Zymeworks (NYSE:ZYME) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends. Which has stronger earnings & valuation, ZYME or SCPH? scPharmaceuticals has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZymeworks$93.38M10.08-$118.67M-$1.49-9.07scPharmaceuticals$41.98M6.99-$85.15M-$1.91-2.91 Does the media favor ZYME or SCPH? In the previous week, Zymeworks and Zymeworks both had 2 articles in the media. scPharmaceuticals' average media sentiment score of 1.75 beat Zymeworks' score of 0.33 indicating that scPharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral scPharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate ZYME or SCPH? Zymeworks presently has a consensus target price of $21.00, suggesting a potential upside of 55.38%. scPharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 152.03%. Given scPharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe scPharmaceuticals is more favorable than Zymeworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90scPharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of ZYME or SCPH? 92.9% of Zymeworks shares are held by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are held by institutional investors. 1.9% of Zymeworks shares are held by company insiders. Comparatively, 4.8% of scPharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is ZYME or SCPH more profitable? Zymeworks has a net margin of -182.75% compared to scPharmaceuticals' net margin of -216.24%. Zymeworks' return on equity of -23.00% beat scPharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Zymeworks-182.75% -23.00% -18.04% scPharmaceuticals -216.24%-594.07%-73.54% Which has more risk and volatility, ZYME or SCPH? Zymeworks has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. SummaryZymeworks beats scPharmaceuticals on 10 of the 16 factors compared between the two stocks. Get scPharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCPH vs. The Competition Export to ExcelMetricscPharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$295.11M$3.04B$5.71B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-2.9321.1328.0720.02Price / Sales6.99338.95459.47103.02Price / CashN/A43.2336.5558.97Price / Book20.578.278.615.88Net Income-$85.15M-$55.19M$3.24B$258.50M7 Day Performance12.45%5.50%3.83%2.03%1 Month Performance39.92%17.25%10.40%12.52%1 Year Performance11.55%4.61%34.13%19.07% scPharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPHscPharmaceuticals4.3877 of 5 stars$5.56-4.9%$14.00+152.0%+20.7%$295.11M$41.98M-2.9330News CoveragePositive NewsZYMEZymeworks2.9074 of 5 stars$13.35+0.1%$21.00+57.3%+34.7%$930.27M$93.38M-8.90460Upcoming EarningsORICOric Pharmaceuticals4.637 of 5 stars$10.85-2.3%$18.57+71.2%+8.8%$924.64MN/A-5.8080Positive NewsNAGENiagen Bioscience1.5921 of 5 stars$11.26-0.4%$13.22+17.4%N/A$886.95M$99.60M66.24120MENSJyong BiotechN/A$11.61+16.0%N/AN/A$882.71MN/A0.0031Quiet Period ExpirationSIONSionna TherapeuticsN/A$19.94-2.4%$38.50+93.1%N/A$879.75MN/A0.0035Positive NewsGap UpREPLReplimune Group4.4757 of 5 stars$11.28+2.8%$20.83+84.7%-69.8%$869.58MN/A-3.67210Trending NewsAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeGHRSGH Research2.1357 of 5 stars$16.49+3.9%$32.00+94.1%+22.8%$857.94MN/A-20.8710XERSXeris Biopharma4.0392 of 5 stars$5.44+6.5%$6.25+14.9%+114.5%$850.71M$203.07M-18.13290News CoveragePositive NewsSNDXSyndax Pharmaceuticals3.4242 of 5 stars$9.85+2.7%$34.30+248.2%-57.5%$847.59M$23.68M-2.55110TRVITrevi Therapeutics3.8775 of 5 stars$7.01+7.0%$20.88+197.8%+164.0%$822.20MN/A-15.5820Positive News Related Companies and Tools Related Companies Zymeworks Alternatives Oric Pharmaceuticals Alternatives Niagen Bioscience Alternatives Jyong Biotech Alternatives Sionna Therapeutics Alternatives Replimune Group Alternatives GH Research Alternatives Xeris Biopharma Alternatives Syndax Pharmaceuticals Alternatives Trevi Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCPH) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share scPharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
